Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 18, 2024 08:45 ET | Source: Elevar Therapeutics

Elevar Therapeutics To Present Two Posters From Phase 3 CARES-310 Study at 2024 ASCO Gastrointestinal Cancers Symposium

A post hoc analysis found the efficacy of camrelizumab plus rivoceranib was superior to sorafenib regardless of baseline liver function as measured by both albumin-bilirubin grade and Child-Pugh...
January 24, 2020 07:30 ET | Source: Bellicum Pharmaceuticals, Inc.

Bellicum Presents New Translational Data for BPX-601 at ASCO GI Cancers Symposium

HOUSTON, Jan. 24, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today presented new Phase 1...
January 18, 2019 10:00 ET | Source: Kura Oncology, Inc.

Kura Oncology Reports Clinical Activity of Tipifarnib in Subsets of Pancreatic Cancer Associated with High CXCL12 Expression

– Tipifarnib is a CXCL12 pathway inhibitor that may provide clinical benefit in subsets of patients with pancreatic cancer – – Analysis of a previously conducted, randomized Phase 3 trial reveals...
January 14, 2019 17:44 ET | Source: ASLAN Pharmaceuticals Limited

ASLAN Pharmaceuticals to Present Positive varlitinib Data in First-Line Biliary Tract Cancer in Combination With Chemotherapy at ASCO GI

Objective Response Rate of 60% and Disease Control Rate of 100% observed in 300mg dose cohortData demonstrate increased activity of varlitinib in combination with gem/cis compared to standard of care ...
November 27, 2018 04:47 ET | Source: ASLAN Pharmaceuticals Limited

ASLAN Pharmaceuticals Announces Acceptance of Abstracts on New Varlitinib Data in BTC at ASCO Gastrointestinal Cancers Symposium

SINGAPORE, Nov. 27, 2018 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and...
January 22, 2016 08:30 ET | Source: OncoMed Pharmaceuticals, Inc.

OncoMed Presents Updated Phase 1b Data for Demcizumab in First-Line Pancreatic Cancer at the Gastrointestinal Cancers Symposium

REDWOOD CITY, Calif., Jan. 22, 2016 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ:OMED), a clinical-stage company developing novel anti-cancer stem cell and immuno-oncology...